245 related articles for article (PubMed ID: 16524945)
1. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
Abrey LE; Childs BH; Paleologos N; Kaminer L; Rosenfeld S; Salzman D; Finlay JL; Gardner S; Peterson K; Hu W; Swinnen L; Bayer R; Forsyth P; Stewart D; Smith AM; Macdonald DR; Weaver S; Ramsay DA; Nimer SD; DeAngelis LM; Cairncross JG
Neuro Oncol; 2006 Apr; 8(2):183-8. PubMed ID: 16524945
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
Abrey LE; Childs BH; Paleologos N; Kaminer L; Rosenfeld S; Salzman D; Finlay JL; Gardner S; Peterson K; Hu W; Swinnen L; Bayer R; Forsyth P; Stewart D; Smith AM; Macdonald DR; Weaver S; Ramsey DA; Nimer SD; DeAngelis LM; Cairncross JG
J Neurooncol; 2003 Nov; 65(2):127-34. PubMed ID: 14686732
[TBL] [Abstract][Full Text] [Related]
3. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
4. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
Modak S; Gardner S; Dunkel IJ; Balmaceda C; Rosenblum MK; Miller DC; Halpern S; Finlay JL
J Clin Oncol; 2004 May; 22(10):1934-43. PubMed ID: 15143087
[TBL] [Abstract][Full Text] [Related]
5. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
[TBL] [Abstract][Full Text] [Related]
6. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
Yamamoto M; Iwaasa M; Nonaka M; Tsugu H; Nabeshima K; Fukushima T
Anticancer Res; 2005; 25(6A):3715-23. PubMed ID: 16302731
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
9. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
12. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Zander T; Nettekoven W; Kraus JA; Pels H; Ko YD; Vetter H; Klockgether T; Schlegel U
J Neurol; 2002 Aug; 249(8):1055-7. PubMed ID: 12195453
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.
Brandes AA; Tosoni A; Vastola F; Pasetto LM; Coria B; Danieli D; Iuzzolino P; Gardiman M; Talacchi A; Ermani M
Cancer; 2004 Nov; 101(9):2079-85. PubMed ID: 15372474
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Yang SH; Hong YK; Yoon SC; Kim BS; Lee YS; Lee TK; Lee KS; Jeun SS; Kim MC; Park CK
Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
[TBL] [Abstract][Full Text] [Related]
15. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
Webre C; Shonka N; Smith L; Liu D; De Groot J
Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
Mohile NA; Forsyth P; Stewart D; Raizer JJ; Paleologos N; Kewalramani T; Louis DN; Cairncross JG; Abrey LE
J Neurooncol; 2008 Sep; 89(2):187-93. PubMed ID: 18458821
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Soussain C; Hoang-Xuan K; Taillandier L; Fourme E; Choquet S; Witz F; Casasnovas O; Dupriez B; Souleau B; Taksin AL; Gisselbrecht C; Jaccard A; Omuro A; Sanson M; Janvier M; Kolb B; Zini JM; Leblond V;
J Clin Oncol; 2008 May; 26(15):2512-8. PubMed ID: 18413641
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Gill P; Litzow M; Buckner J; Arndt C; Moynihan T; Christianson T; Ansell S; Galanis E
Cancer; 2008 Apr; 112(8):1805-11. PubMed ID: 18300237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
